Third Quarter 2024 Financial and Operating Results for the Three Months Ended September 30, 2024 U.S. treatment session revenue for the three months ended September 30, 2024 was $13.3 million, an ...
(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ... with $2.65 million from recurring revenue, which consists of the sale of ...